Features of obesity treatment in patients with gastroesophageal reflux disease
In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
E I Andreeva [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Kazanskij Medicinskij Žurnal - ECO-vector, 2018, 99(2018), 1, Seite 78-84 |
|---|---|
| Übergeordnetes Werk: |
volume:99 ; year:2018 ; number:1 ; pages:78-84 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.17816/KMJ2018-078 |
|---|
| Katalog-ID: |
DOAJ051587688 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ051587688 | ||
| 003 | DE-627 | ||
| 005 | 20230308162024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2018 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17816/KMJ2018-078 |2 doi | |
| 035 | |a (DE-627)DOAJ051587688 | ||
| 035 | |a (DE-599)DOAJfe942368e2224173a06ea5df84ab392f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a E I Andreeva |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Features of obesity treatment in patients with gastroesophageal reflux disease |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs. | ||
| 650 | 4 | |a гастроэзофагеальная рефлюксная болезнь | |
| 650 | 4 | |a ожирение | |
| 650 | 4 | |a метаболический синдром | |
| 650 | 4 | |a ингибиторы протонной помпы | |
| 650 | 4 | |a лечение | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 773 | 0 | 8 | |i In |t Kazanskij Medicinskij Žurnal |d ECO-vector, 2018 |g 99(2018), 1, Seite 78-84 |w (DE-627)1760612359 |x 25879359 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2018 |g number:1 |g pages:78-84 |
| 856 | 4 | 0 | |u https://doi.org/10.17816/KMJ2018-078 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/fe942368e2224173a06ea5df84ab392f |z kostenfrei |
| 856 | 4 | 0 | |u https://journals.eco-vector.com/kazanmedj/article/view/7813 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0368-4814 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2587-9359 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2018 |e 1 |h 78-84 | ||
| author_variant |
e i a eia |
|---|---|
| matchkey_str |
article:25879359:2018----::etrsfbsttetetnainsihatosp |
| hierarchy_sort_str |
2018 |
| publishDate |
2018 |
| allfields |
10.17816/KMJ2018-078 doi (DE-627)DOAJ051587688 (DE-599)DOAJfe942368e2224173a06ea5df84ab392f DE-627 ger DE-627 rakwb rus E I Andreeva verfasserin aut Features of obesity treatment in patients with gastroesophageal reflux disease 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs. гастроэзофагеальная рефлюксная болезнь ожирение метаболический синдром ингибиторы протонной помпы лечение Medicine R In Kazanskij Medicinskij Žurnal ECO-vector, 2018 99(2018), 1, Seite 78-84 (DE-627)1760612359 25879359 nnns volume:99 year:2018 number:1 pages:78-84 https://doi.org/10.17816/KMJ2018-078 kostenfrei https://doaj.org/article/fe942368e2224173a06ea5df84ab392f kostenfrei https://journals.eco-vector.com/kazanmedj/article/view/7813 kostenfrei https://doaj.org/toc/0368-4814 Journal toc kostenfrei https://doaj.org/toc/2587-9359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 99 2018 1 78-84 |
| spelling |
10.17816/KMJ2018-078 doi (DE-627)DOAJ051587688 (DE-599)DOAJfe942368e2224173a06ea5df84ab392f DE-627 ger DE-627 rakwb rus E I Andreeva verfasserin aut Features of obesity treatment in patients with gastroesophageal reflux disease 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs. гастроэзофагеальная рефлюксная болезнь ожирение метаболический синдром ингибиторы протонной помпы лечение Medicine R In Kazanskij Medicinskij Žurnal ECO-vector, 2018 99(2018), 1, Seite 78-84 (DE-627)1760612359 25879359 nnns volume:99 year:2018 number:1 pages:78-84 https://doi.org/10.17816/KMJ2018-078 kostenfrei https://doaj.org/article/fe942368e2224173a06ea5df84ab392f kostenfrei https://journals.eco-vector.com/kazanmedj/article/view/7813 kostenfrei https://doaj.org/toc/0368-4814 Journal toc kostenfrei https://doaj.org/toc/2587-9359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 99 2018 1 78-84 |
| allfields_unstemmed |
10.17816/KMJ2018-078 doi (DE-627)DOAJ051587688 (DE-599)DOAJfe942368e2224173a06ea5df84ab392f DE-627 ger DE-627 rakwb rus E I Andreeva verfasserin aut Features of obesity treatment in patients with gastroesophageal reflux disease 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs. гастроэзофагеальная рефлюксная болезнь ожирение метаболический синдром ингибиторы протонной помпы лечение Medicine R In Kazanskij Medicinskij Žurnal ECO-vector, 2018 99(2018), 1, Seite 78-84 (DE-627)1760612359 25879359 nnns volume:99 year:2018 number:1 pages:78-84 https://doi.org/10.17816/KMJ2018-078 kostenfrei https://doaj.org/article/fe942368e2224173a06ea5df84ab392f kostenfrei https://journals.eco-vector.com/kazanmedj/article/view/7813 kostenfrei https://doaj.org/toc/0368-4814 Journal toc kostenfrei https://doaj.org/toc/2587-9359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 99 2018 1 78-84 |
| allfieldsGer |
10.17816/KMJ2018-078 doi (DE-627)DOAJ051587688 (DE-599)DOAJfe942368e2224173a06ea5df84ab392f DE-627 ger DE-627 rakwb rus E I Andreeva verfasserin aut Features of obesity treatment in patients with gastroesophageal reflux disease 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs. гастроэзофагеальная рефлюксная болезнь ожирение метаболический синдром ингибиторы протонной помпы лечение Medicine R In Kazanskij Medicinskij Žurnal ECO-vector, 2018 99(2018), 1, Seite 78-84 (DE-627)1760612359 25879359 nnns volume:99 year:2018 number:1 pages:78-84 https://doi.org/10.17816/KMJ2018-078 kostenfrei https://doaj.org/article/fe942368e2224173a06ea5df84ab392f kostenfrei https://journals.eco-vector.com/kazanmedj/article/view/7813 kostenfrei https://doaj.org/toc/0368-4814 Journal toc kostenfrei https://doaj.org/toc/2587-9359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 99 2018 1 78-84 |
| allfieldsSound |
10.17816/KMJ2018-078 doi (DE-627)DOAJ051587688 (DE-599)DOAJfe942368e2224173a06ea5df84ab392f DE-627 ger DE-627 rakwb rus E I Andreeva verfasserin aut Features of obesity treatment in patients with gastroesophageal reflux disease 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs. гастроэзофагеальная рефлюксная болезнь ожирение метаболический синдром ингибиторы протонной помпы лечение Medicine R In Kazanskij Medicinskij Žurnal ECO-vector, 2018 99(2018), 1, Seite 78-84 (DE-627)1760612359 25879359 nnns volume:99 year:2018 number:1 pages:78-84 https://doi.org/10.17816/KMJ2018-078 kostenfrei https://doaj.org/article/fe942368e2224173a06ea5df84ab392f kostenfrei https://journals.eco-vector.com/kazanmedj/article/view/7813 kostenfrei https://doaj.org/toc/0368-4814 Journal toc kostenfrei https://doaj.org/toc/2587-9359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 99 2018 1 78-84 |
| language |
Russian |
| source |
In Kazanskij Medicinskij Žurnal 99(2018), 1, Seite 78-84 volume:99 year:2018 number:1 pages:78-84 |
| sourceStr |
In Kazanskij Medicinskij Žurnal 99(2018), 1, Seite 78-84 volume:99 year:2018 number:1 pages:78-84 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
гастроэзофагеальная рефлюксная болезнь ожирение метаболический синдром ингибиторы протонной помпы лечение Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Kazanskij Medicinskij Žurnal |
| authorswithroles_txt_mv |
E I Andreeva @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
1760612359 |
| id |
DOAJ051587688 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ051587688</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308162024.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17816/KMJ2018-078</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ051587688</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfe942368e2224173a06ea5df84ab392f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E I Andreeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Features of obesity treatment in patients with gastroesophageal reflux disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">гастроэзофагеальная рефлюксная болезнь</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ожирение</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">метаболический синдром</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ингибиторы протонной помпы</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">лечение</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Kazanskij Medicinskij Žurnal</subfield><subfield code="d">ECO-vector, 2018</subfield><subfield code="g">99(2018), 1, Seite 78-84</subfield><subfield code="w">(DE-627)1760612359</subfield><subfield code="x">25879359</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:99</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:78-84</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17816/KMJ2018-078</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fe942368e2224173a06ea5df84ab392f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://journals.eco-vector.com/kazanmedj/article/view/7813</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0368-4814</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-9359</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">99</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">78-84</subfield></datafield></record></collection>
|
| author |
E I Andreeva |
| spellingShingle |
E I Andreeva misc гастроэзофагеальная рефлюксная болезнь misc ожирение misc метаболический синдром misc ингибиторы протонной помпы misc лечение misc Medicine misc R Features of obesity treatment in patients with gastroesophageal reflux disease |
| authorStr |
E I Andreeva |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760612359 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
25879359 |
| topic_title |
Features of obesity treatment in patients with gastroesophageal reflux disease гастроэзофагеальная рефлюксная болезнь ожирение метаболический синдром ингибиторы протонной помпы лечение |
| topic |
misc гастроэзофагеальная рефлюксная болезнь misc ожирение misc метаболический синдром misc ингибиторы протонной помпы misc лечение misc Medicine misc R |
| topic_unstemmed |
misc гастроэзофагеальная рефлюксная болезнь misc ожирение misc метаболический синдром misc ингибиторы протонной помпы misc лечение misc Medicine misc R |
| topic_browse |
misc гастроэзофагеальная рефлюксная болезнь misc ожирение misc метаболический синдром misc ингибиторы протонной помпы misc лечение misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Kazanskij Medicinskij Žurnal |
| hierarchy_parent_id |
1760612359 |
| hierarchy_top_title |
Kazanskij Medicinskij Žurnal |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760612359 |
| title |
Features of obesity treatment in patients with gastroesophageal reflux disease |
| ctrlnum |
(DE-627)DOAJ051587688 (DE-599)DOAJfe942368e2224173a06ea5df84ab392f |
| title_full |
Features of obesity treatment in patients with gastroesophageal reflux disease |
| author_sort |
E I Andreeva |
| journal |
Kazanskij Medicinskij Žurnal |
| journalStr |
Kazanskij Medicinskij Žurnal |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| container_start_page |
78 |
| author_browse |
E I Andreeva |
| container_volume |
99 |
| format_se |
Elektronische Aufsätze |
| author-letter |
E I Andreeva |
| doi_str_mv |
10.17816/KMJ2018-078 |
| title_sort |
features of obesity treatment in patients with gastroesophageal reflux disease |
| title_auth |
Features of obesity treatment in patients with gastroesophageal reflux disease |
| abstract |
In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs. |
| abstractGer |
In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs. |
| abstract_unstemmed |
In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
Features of obesity treatment in patients with gastroesophageal reflux disease |
| url |
https://doi.org/10.17816/KMJ2018-078 https://doaj.org/article/fe942368e2224173a06ea5df84ab392f https://journals.eco-vector.com/kazanmedj/article/view/7813 https://doaj.org/toc/0368-4814 https://doaj.org/toc/2587-9359 |
| remote_bool |
true |
| ppnlink |
1760612359 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.17816/KMJ2018-078 |
| up_date |
2024-07-03T21:12:19.661Z |
| _version_ |
1803593858063269888 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ051587688</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308162024.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17816/KMJ2018-078</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ051587688</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfe942368e2224173a06ea5df84ab392f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E I Andreeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Features of obesity treatment in patients with gastroesophageal reflux disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the past few decades, the worldwide prevalence of such nosological forms as gastroesophageal reflux disease and obesity has been increasing. The combination of these pathologies is more often observed in patients who have nutrition and lifestyle issues, as well as genetic predisposition to these nosologies. Patients with obesity are noted to have predisposition to diaphragmatic hernias and mechanical damage of gastroesophageal junction, which occurs against the background of increased intragastric pressure and increased pressure gradient between the stomach and esophagus, as well as due to extension of the proximal part of the stomach. One of the basic pathogenetic moments of gastroesophageal reflux disease is spontaneous relaxation of the lower esophageal sphincter. According to recent studies, in obesity the frequency of postprandial spontaneous relaxation of the lower esophageal sphincter increases even in the absence of diaphragmatic hernia, non-erosive gastroesophageal reflux disease and reflux esophagitis. The variety of metabolic disorders observed in these patients requires a comprehensive approach to treatment, aimed both at effective reduction of the acid-peptic factor and at correction of excessive body weight. Both non-pharmacological and pharmacological methods are distinguished among the main treatment directions for both components of this combined pathology. An important role in therapy is given to activities that contribute to the maintenance of healthy lifestyle: smoking cessation, weight loss, dietary nutrition, health-improving physical culture. Among medications for patients with gastroesophageal reflux disease and obesity, which allow achieving an optimal acid-reducing effect, specific attention is assigned to a group of proton pump inhibitors (H+/K+-ATPase inhibitors), which have a lower affinity for hepatic cytochrome P450 enzyme system, do not affect its activity and do not clinically significantly cross-react with other drugs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">гастроэзофагеальная рефлюксная болезнь</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ожирение</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">метаболический синдром</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ингибиторы протонной помпы</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">лечение</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Kazanskij Medicinskij Žurnal</subfield><subfield code="d">ECO-vector, 2018</subfield><subfield code="g">99(2018), 1, Seite 78-84</subfield><subfield code="w">(DE-627)1760612359</subfield><subfield code="x">25879359</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:99</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:78-84</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17816/KMJ2018-078</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fe942368e2224173a06ea5df84ab392f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://journals.eco-vector.com/kazanmedj/article/view/7813</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0368-4814</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2587-9359</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">99</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">78-84</subfield></datafield></record></collection>
|
| score |
7.4031916 |